
Simplifying and Improving Global Pharma Operations
Key Takeaways
- Understand how combining stationary and in-transit temperature data into a single, product-level view can support faster and more informed release decisions across the pharmaceutical supply chain.
- Recognize how applying individual stability budgets per product can reduce waste and minimize manual data assessment efforts.
Supply chain data across stationary and in-transit monitoring can accelerate product release and reduce waste for pharma companies.
Sponsored by Elpro
Christoph Bamert, Chief Sales Officer at Elpro, explains safeguarding pharmaceutical products throughout the entire supply chain by providing visibility across both stationary and in-transit monitoring stages. By aggregating temperature and stability data in one place, pharma companies can see into a single, product-level view. Tracking individual stability budgets per product rather than applying strict alarms broadly accelerates release processes and reduce unnecessary quarantine times. Ambient temperature monitoring of the outside of passive packaging has emerged as a particularly valuable tool for identifying lane risks, delays, and whether products remain in controlled environments. The industry is shifting from traditional monitoring toward a data-driven approach that enables automated, product-based release decisions across the full pharmaceutical journey.




